grant
Monoclonal Antibody Therapeutics for Candida auris
Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 1 Aug 2025Deadline 30 Jun 2030
NIHUS FederalResearch GrantFY2025AIDS VirusAb-mediated immunityAb-mediated protectionAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAffinityAmBAmBisomeAmphocilAmphotecAmphotercin BAmphotericin BAnthraxAnthrax diseaseAnti-microbial Drug ResistanceAnti-microbial Drug ResistantAntibiotic ResistanceAntibodiesAntibody TherapyAntibody immunityAntibody protectionAntibody-mediated protectionAntifungal TherapyAntigenic DeterminantsAntimicrobial Drug ResistanceAntimicrobial Drug ResistantAssayAzole resistanceAzole resistantAzolesBacteriaBindingBinding DeterminantsBioassayBiochemicalBiological AssayC albicansC aurisC diffC difficileC neoformansC. albicansC. aurisC. diffC. difficileC. neoformansC.albicansCandidaCandida albicansCandida aurisCell BodyCell Mediated ImmunologyCell surfaceCell-Mediated ImmunityCellsCellular ImmunityCharacteristicsClinicalClinical Treatment MoabClinical TrialsClostridioides difficileClostridium difficileCommunicable DiseasesComplementComplement ProteinsCryptococcusCryptococcus neoformansDeath RateDevelopmentDiseaseDisorderDrug TargetingDrug resistanceDrugsEBOVEbola virusEbola-like VirusesEpitopesFungal Drug ResistanceFungizoneFungus drug resistantFutureGeneralized GrowthGenomicsGlobal WarmingGoalsGrowthH capsulatumH. capsulatumHIVHistoplasma capsulatumHistoryHospital AdmissionHospitalizationHuman Immunodeficiency VirusesHumoral ImmunitiesIg GenesImmune mediated therapyImmunityImmunochemical ImmunologicImmunoglobulin GenesImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunoradiotherapyImmunotherapyImpairmentIn VitroIndividualInfectionInfectious DiseasesInfectious DisorderLAV-HTLV-IIILaboratoriesLibrariesLicensingLymphadenopathy-Associated VirusMAb TherapeuticsMacrophageMedicationMedicineMelaninsMelanoma CellMiceMice MammalsMicrobial Drug ResistanceMolecular InteractionMoniliaMonoclonal AntibodiesMorbidityMorbidity - disease rateMurineMusMysteclin-FMφOrganOrthoebolavirusOutcomePatientsPhagocytosisPharmaceutical PreparationsPhylogenetic AnalysisPhylogeneticsPolyenesPredispositionPreparationProteinsRadioimmunotherapyRecording of previous eventsReportingResistanceResistance to antibioticsResistant to antibioticsRespiratory syncytial virusSuggestionSurfaceSusceptibilityTestingTherapeutic AgentsTherapeutic FungicidesTherapeutic Monoclonal AntibodiesTissue GrowthTorulaUnited StatesVaccinesVirusVirus-HIVWorkWorld Health OrganizationYeastsanti-fungalanti-fungal agentsanti-fungal druganti-fungal drug resistanceanti-fungal drug resistantanti-fungal resistanceanti-fungal resistantanti-microbialantibiotic drug resistanceantibiotic resistantantibody based therapiesantibody treatmentantibody-based immunityantibody-based therapeuticsantibody-based treatmentantibody-mediated immunityantimicrobialcandidate identificationclinical candidateclinical developmentcomplementationdevelopmentaldrug candidatedrug resistantdrug/agentemerging pathogenexperiencefungal infectious disease treatmentfungal pathogenfungi pathogenfungicidalfungicidefungusfungus drug resistancehistorieshospitalization ratesimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyinfectious disease treatmentknowledge basemAbsmicrobial drug resistantmonoclonal Absmonoclonal antibody drugsmortalitymortality ratemortality rationew approachesnew drug treatmentsnew drugsnew pathogennew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel approachesnovel drug treatmentsnovel drugsnovel pathogennovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeuticsnovel therapyontogenypathogenic funguspolyclonal antibodypre-clinical developmentpreclinical developmentpreparationspriority pathogenresistance to Drugresistance to anti-fungalresistance to azoleresistantresistant to Drugresistant to anti-fungalresistant to azolesmall moleculesynergismtherapeutic mAbs
Description preview
SUMMARY
In the past decade Candida auris has emerged a new pathogenic fungus that causes disease
associated with high morbidity and mortality. C. auris has an intrinsic resistance to azoles and
polyenes, leaving echinocandins as the only reliably effective class of antifungal agents.
Unfortunately, drug resistance to echinocandins is rising…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click